PBYI

Analyst Note: Puma Biotechnology, Inc. (PBYI)

Date: 2026-06-13 Current Price: $7.56

1. Structural Readiness

• Conservative Entry: Not yet actionable. A conservative entry requires a confirmed breakout above the resistance level defined by the coil structure.
• Aggressive/Pre-Breakout Entry: Not recommended as a standalone signal; the setup is incomplete.
• Breakout Level: Not yet triggered.
• Current Price: $7.56.
• Extension: Not applicable (price has not extended from a confirmed breakout).
• ATR Context: Current ATR is 3.7% (productive). This sits within the historical "sweet spot" (4–6% is ideal, but 3.7% is acceptable for sizing), indicating manageable volatility for position sizing without the extreme risk associated with >8% ATR.

2. Thesis Layer

As of 2026-06-13, PBYI is classified as a TACTICAL, setup-led name. There is no named secular thesis attached to this specific setup in the current evidence base. The investment case must be judged strictly on the quality of the technical setup (the forming coil) and the immediate business fundamentals provided in the earnings and filing data. No macro or thematic thesis should be invented to support the position; the conviction rests on the structural readiness and the specific management guidance provided in Q1 2026.

3. Business Overview

Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments for cancer, specifically focusing on HER2-positive breast cancer.

• Core Product: The company commercializes NERLYNX (neratinib), an oral version of neratinib, for the treatment of certain HER2-positive breast cancers.
• *Evidence:* As of December 31, 2025, NERLYNX has received approval in more than 40 countries outside the United States, including the EU, China, Latin America, Australia, Canada, and Hong Kong (E13).
• *Commercial Model:* The company sells NERLYNX to a limited number of specialty pharmacies and distributors in the U.S., who then resell to patients and medical centers (E11).
• Pipeline & Development:
• Alisertib: The company holds global development and commercialization rights for alisertib, a selective small molecule inhibitor of Aurora Kinase A designed to disrupt mitosis (E9, E10).
• ALISCA-Lung1: Management anticipates additional interim efficacy data from the ALISCA-Lung1 trial in the second half of 2026 or the first half of 2027 (E1).
• New Trial Initiation: Management is hoping to initiate a new trial in the second half of 2026 (E2).
• Financial Performance (Q1 2026):
• Revenue: Net product revenue was $42 million in Q1 2026, a decline from $59.9 million in Q4 2025 and $43.1 million in Q1 2025 (E6).
• Volume: 2,328 bottles of NERLYNX were sold in Q1 2026, down from 3,298 bottles in Q4 2025 (E7).
• Prescription Trends: Despite total prescription volume being down ~4% compared to Q4 2025, *new* prescriptions were up approximately 25% compared to Q4 2025 (E8).
• Guidance (FY 2026):
• Revenue: Management anticipates net NERLYNX product revenue of $202 million to $206 million, an increase from prior guidance of $194 million to $198 million (E4).
• Net Income: Management expects full-year net income of $16 million to $19 million, up from prior guidance of $10 million to $13 million (E5).

4. Archetype and Conviction

• Archetype: Quality Compounder (with elements of a Margin Inflector).
• *Rationale:* The company is demonstrating an ability to improve profitability (net income guidance raised) and revenue guidance despite a sequential decline in Q1 sales volume. The "new prescription" uptick (+25%) suggests a potential inflection in market penetration or patient acquisition that has not yet fully translated to top-line revenue in the quarterly snapshot.
• Valuation Context:
• Forward consensus EPS for FY1 is $0.29 and FY2 is $0.20 (E20).
• At a price of $7.56, the stock trades at approximately 26x FY1 consensus EPS. This valuation is supported by the raised guidance for profitability, suggesting the market is pricing in the successful commercialization of NERLYNX and the potential for future pipeline milestones.
• Conviction Stack:
• Thesis Strength: Low (Tactical only, no secular theme).
• Evidence Quality: High (Specific, quantitative guidance from Q1 2026 earnings).
• Structural Quality: Moderate (Forming coil, not confirmed).
• Rerating Potential: Moderate. The raised guidance provides a fundamental floor, but the technical breakout is required to trigger the momentum.

5. Invalidations, Strengths, and Gaps

• What Would Strengthen the Case:
• A confirmed price breakout above the coil resistance level (triggering the "Confirmed" state).
• Positive interim data readouts from the ALISCA-Lung1 trial in the second half of 2026.
• Continued growth in "new prescriptions" translating to higher sequential revenue in Q2 2026.
• What Would Invalidate the Case:
• A significant miss on the FY 2026 revenue or income guidance in subsequent quarters.
• Failure to initiate the anticipated trial in the second half of 2026.
• Gaps in Evidence:
• Breakout Level: The specific resistance level required for a confirmed breakout is not quantified.
• Cash Runway: While net income is positive, specific details on cash burn or runway beyond the current guidance are not explicitly detailed in the provided snippets.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key risks: Technical setup is incomplete (forming, not confirmed); Q1 revenue declined sequentially to $42 million; reliance on limited specialty pharmacy customers; pipeline data (ALISCA-Lung1) not yet available. Sizing hint: Position size should be conservative given the "forming" status; treat as a partial allocation pending a confirmed breakout. Expected path: Management expects revenue and income growth to continue through FY2026; if price breaks out of the coil structure, momentum may accelerate toward the next resistance level. Expected horizon: 3 to 6 months for the technical setup to resolve (breakout or invalidation) and for the next earnings cycle to confirm the guidance trajectory.